Skip to main content
Publications
Gini R, Pajouheshnia R , Gardarsdottir H, Bennett D, Li L, Gulea C, Wientzek-Fleischmann A, Bazelier MT, Burcu M, Dodd C, Duran CE, Kaplan S, Lanes S, Marinier K, Roberto G, Soman K, Zhou X, Platt R, Setoguchi S, Hall GC. Describing diversity of real world data sources in pharmacoepidemiologic studies: the DIVERSE scoping review . Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5787. doi: 10.1002/pds.5787
de Vogel S, Seeger JD, Arana A , Margulis AV , McQuay LJ, Perez-Gutthann S , Hallas J, Kristiansen NS, Linder M, Odsbu I, Suehs B, Xu Y, Uribe C, Appenteng K, Robinson NJ. Lessons learned from a multi-data source research collaboration: the mirabegron post-authorization safety study program . Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5799. doi: 10.1002/pds.5799
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E , Kirker M, Houghton K , Le Moine JG , Chang J, Yarr S , Barnett C , Mladsi D . Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N , Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488] . Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010
Boeri M, Marcek T, Chintakayala PK , Poulos C , Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S. Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S313. doi: 10.1016/j.jval.2023.09.1653
Handels R, Herring W , Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I. IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias . Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S419. doi: 10.1016/j.jval.2023.09.2194
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A , Lyall M, Nuabor W , D'Souza V , Dubucq H, Moola S. Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S549-50. doi: 10.1016/j.jval.2023.09.2953
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A , Lyall M, Nuabor W , D'Souza V , Dubucq H, Moola S. Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplment):S553. doi: 10.1016/j.jval.2023.09.2970
Sherif B , Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M , Odom D , Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1 . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Kawai A , Fuller CC, Koram N, Agan A, Brown J, Burk J, Cai B, Daniels K, Fearrington J, Franklin JM, Hague C, Jamal-Allial A, Johannes CB , Kempner M, Layton JB , Ma Q, Mai X, Mayer SE, Pawloski PA, Reynolds JS, Seals RM, Selvan M, Smith S, McMahill-Walraven CN, Gilsenan A , Platt R. Monitoring results from a postapproval safety study of Pfizer-BioNTech COVID-19 vaccine in the United States: vaccine utilization and incidence rates of myocarditis/pericarditis . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):182. doi: 10.1002/pds.5687
Tormos A , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia Esteban R , Plana E , Farsani SF, Perez-Gutthann S , Pladevall-Vila M , Rebordosa C . Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687
Mayer SE, Fuller CC, Haynes K, Alam S, Brown JS, Daniels K, Hawrusik R, Horgan C, Jamal-Allial A, Johannes CB , Kawai AT , Layton JB , Mai X, Marshall J, McMahill-Walraven CN, Reynolds JS, Seals R, Selvan M, Stemkowski S, Wang FT, Yost E, Gilsenan A , Platt R. Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):186. doi: 10.1002/pds.5687
Weibel D, De Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E , Garcia de Albeniz Martinez X , Weinrib R , Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A . Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687
Saltus C , Djibo DA, Peetluk L, Kaye J, McMahill-Walraven C, Johannes C , Bernick B, Calingaert B , Franklin J, Graham S, Pigoga J, Shuminski P, Margulis AV . Use of very low-dose vaginal estrogens among postmenopausal women in the US . Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):352-3. doi: 10.1002/pds.5687
Levesque L, Johannes CB , Lecciones JA, Giamberardino H, Marcelon L, Cohen C, Rojas A, Bennett L , Khromava A. Post-authorization safety study: cohort event monitoring for CYD-TDV dengue vaccine (DNG15) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):592. doi: 10.1002/pds.5687
Ahmadizar F, Fortuny J , Cid-Royo A, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687
Ogilvie RP, Layton JB , Wong HL, Jiao Y, Parambi RJ, Deng J, Miller M, Song J, Lloyd PC, Weatherby L, Peetluk LS, Bell EJ, Yang G, Amend KL, Kawai A , Lo AC, Matuska K, Wernecke M, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Anthony MS , Chillarige Y, Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 vaccine in US children aged 5-17 years . Presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):78. doi: 10.1002/pds.5687